Tau PET Performs Well in Predicting Dementia in Individuals With MCI
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 12, 2024 -- Tau positron emission tomography (PET) has the best performance as a standalone marker for prediction of progression of mild cognitive impairment (MCI) to dementia, according to a study published online June 10 in JAMA Neurology.
Colin Groot, Ph.D. from Lund University in Sweden, and colleagues examined the prognostic value of tau PET to predict clinical progression from MCI to dementia in a multicenter cohort study with external validation. The study included 448 eligible individuals with MCI (331 and 117 in the discovery and validation cohorts, respectively).
The researchers found that the mean Mini-Mental State Examination (MMSE) score was 27.1 in the discovery cohort, and 110 individuals (33 percent) with MCI converted to dementia (71 to Alzheimer disease [AD] dementia). All-cause dementia was better predicted by the model with tau PET (area under the receiver operating characteristic curve [AUC], 0.75) than a base model including age, sex, education, and MMSE score (AUC, 0.71), while prediction was not improved with models assessing the other neuroimaging markers. Tau PET replicated prediction of all-cause mortality in the validation cohort. Compared with the base model (AUC, 0.75), there was significant improvement noted in prediction of AD dementia in the model including tau PET, tau PET visual read, and β-amyloid PET Centiloids (AUCs, 0.84, 0.83, and 0.83, respectively). Only the tau PET and tau PET visual reads replicated prediction of AD dementia in the validation cohort.
"Our findings constitute a next step toward the ultimate goal of accurate and individualized prognoses, which may reduce uncertainty and lower disease burden for individuals with MCI," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.